An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV

NCT ID: NCT00027365

Last Updated: 2021-10-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 84 participants
• Study Classification: INTERVENTIONAL
• Study Completion Date: 2003-06-30

Brief Summary

The purpose of this study is to see if the investigational vaccines NefTat and gp120w61d are safe and tolerable in humans and to see how the immune system responds to the vaccines.

There have been advances in the treatment and prevention of HIV, but the spread of HIV/AIDS is getting worse. HIV/AIDS is the main infectious cause of death in the world. A vaccine to prevent HIV disease is the best way to try to deal with this situation. Several vaccine products have been tested, but only 2 are still in trial. There is a need for a new product.

Detailed Description

Despite recent advances in the treatment and prevention of HIV disease, the epidemic is worsening throughout most of the world. HIV/AIDS is the leading cause of death in sub-Saharan Africa and the leading infectious cause of death in the world. An effective and inexpensive vaccine to prevent HIV disease remains as the best option to try to deal with this expanding epidemic. A number of vaccine products have been tested; however, only 2 have progressed to a Phase III trial, underscoring the need for new vaccine strategies.

Prior to study entry, participants have their risk status for HIV infection determined by a series of questions. Further eligibility is determined by results of physical exam, laboratory tests, and further questions. Blood is drawn on each study visit. Participants are assigned randomly to 1 of 4 study groups:

Group I: NefTat or placebo. Groups II, III, and IV: NefTat and gp120 or placebo. Each group receives a different concentration of gp120.

All immunizations are admixed with AS02A adjuvant. Vaccinations are administered intramuscularly at 3 time points (entry, 1 month, and 3 months). Product safety and immunogenicity are performed at designated time points; participants have about 11 clinic visits.

Conditions

HIV Infections

Study Design

• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Interventions

Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A

Intervention Type: BIOLOGICAL

NefTat

Intervention Type: BIOLOGICAL

AS02A Adjuvant

Intervention Type: DRUG

gp120W61D

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

Participants may be eligible for this study if they:

• Are between 18 and 60 years of age.
• Are in good general health and meet laboratory test requirements.
• Have a CD4 count of 400 or more cells/mm3.
• Agree to use at least 1 of the following methods of contraception for at least 21 days before enrollment until the last protocol visit: condoms (male or female) with or without a spermicide, diaphragm or cervical cap with spermicide, IUD, or hormonal-based therapy (applies to women who are able to have children).
• Have access to a participating site and are willing to have follow-up for the entire study (12 months).
• Answer questions about their understanding of the study.
• Do not have hepatitis B or C.
• Are HIV-uninfected.

Exclusion Criteria

Participants may not be eligible for this study if they:

• Are pregnant or breast-feeding.
• Have recently received a vaccine.
• Have used experimental agents within 30 days before enrollment.
• Have received HIV vaccines or placebo in a previous HIV vaccine study.
• Have received blood products 120 days before HIV screening.
• Have received immunoglobulin (antibodies) 60 days before HIV screening.
• Have serious reactions to vaccines.
• Have problems with their immune system.
• Have cancer.
• Have used drugs that affect the immune system within the past 6 months.
• Have diabetes.
• Have a thyroid disease.
• Have unstable asthma.
• Are taking anti-tuberculosis drugs.
• Have seizures.
• Have a bleeding disorder.
• Have had their spleen removed.
• Have angioedema (a certain type of body tissue swelling).
• Have active syphilis.
• Have high blood pressure (unless controlled by medication).
• Have mental or emotional problems that make them unsuitable for the study.
• Have any medical, mental, or social condition; job responsibilities; or other responsibility that, in the opinion of the doctor, would interfere with the study.
• Have reactions to components of the vaccines.
• Are at high risk for contracting HIV.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tom Evans

Role: STUDY_CHAIR

Locations

Alabama Vaccine CRS

Birmingham, Alabama, United States

San Francisco Vaccine and Prevention CRS

San Francisco, California, United States

Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research, Project SAVE-Baltimore

Baltimore, Maryland, United States

Project Brave HIV Vaccine CRS

Baltimore, Maryland, United States

Brigham and Women's Hosp. CRS

Boston, Massachusetts, United States

Fenway Community Health Clinical Research Site (FCHCRS)

Boston, Massachusetts, United States

Saint Louis Univ. School of Medicine, HVTU

St Louis, Missouri, United States

NY Blood Ctr./Union Square CRS

New York, New York, United States

HIV Prevention & Treatment CRS

New York, New York, United States

Univ. of Rochester HVTN CRS

Rochester, New York, United States

NY Blood Ctr./Bronx CRS

The Bronx, New York, United States

Miriam Hospital's HVTU

Providence, Rhode Island, United States

Vanderbilt Vaccine CRS

Nashville, Tennessee, United States

Infectious Diseases Physicians, Inc.

Annandale, Virginia, United States

FHCRC/UW Vaccine CRS

Seattle, Washington, United States

Countries

United States

References

Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, McElrath MJ, Lu S. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One. 2010 Nov 9;5(11):e13916. doi: 10.1371/journal.pone.0013916.

Reference Type: RESULT

PMID: 21085486 (View on PubMed)

Other Identifiers

10196

Identifier Type: REGISTRY

Identifier Source: secondary_id

HVTN 041

Identifier Type: -

Identifier Source: org_study_id